158 related articles for article (PubMed ID: 38195541)
21. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
22. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia.
Schittenhelm MM; Walter B; Tsintari V; Federmann B; Bajrami Saipi M; Akmut F; Illing B; Mau-Holzmann U; Fend F; Lopez CD; Kampa-Schittenhelm KM
EBioMedicine; 2019 Apr; 42():340-351. PubMed ID: 30952616
[TBL] [Abstract][Full Text] [Related]
23. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
24. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
25. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
26. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.
Patel S; George R; Autore F; Fraternali F; Ladbury JE; Nikolova PV
Nucleic Acids Res; 2008 Sep; 36(16):5139-51. PubMed ID: 18676979
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
28. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
Sill H; Zebisch A; Haase D
Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
[TBL] [Abstract][Full Text] [Related]
29. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
30. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Schmelz K; Wagner M; Dörken B; Tamm I
Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
[TBL] [Abstract][Full Text] [Related]
31. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
Zhang L; McGraw KL; Sallman DA; List AF
Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
[TBL] [Abstract][Full Text] [Related]
32. PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M
Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP.
Vigneron AM; Ludwig RL; Vousden KH
Genes Dev; 2010 Nov; 24(21):2430-9. PubMed ID: 21041411
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia.
Zhou H; Zhang Q; Huang W; He C; Zhou C; Zhou J; Ning Y
Int J Oncol; 2023 May; 62(5):. PubMed ID: 37052262
[TBL] [Abstract][Full Text] [Related]
35. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia.
Xie J; Chen K; Han H; Dong Q; Wang W
Curr Res Transl Med; 2022 Sep; 70(4):103347. PubMed ID: 35483237
[TBL] [Abstract][Full Text] [Related]
36. Lymphatic vessel assembly is impaired in Aspp1-deficient mouse embryos.
Hirashima M; Sano K; Morisada T; Murakami K; Rossant J; Suda T
Dev Biol; 2008 Apr; 316(1):149-59. PubMed ID: 18304521
[TBL] [Abstract][Full Text] [Related]
37. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
38. CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents.
Britos-Bray M; Ramirez M; Cao W; Wang X; Liu PP; Civin CI; Friedman AD
Blood; 1998 Dec; 92(11):4344-52. PubMed ID: 9834241
[TBL] [Abstract][Full Text] [Related]
39. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
Shing DC; Trubia M; Marchesi F; Radaelli E; Belloni E; Tapinassi C; Scanziani E; Mecucci C; Crescenzi B; Lahortiga I; Odero MD; Zardo G; Gruszka A; Minucci S; Di Fiore PP; Pelicci PG
J Clin Invest; 2007 Dec; 117(12):3696-707. PubMed ID: 18037989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
